Dafna Capital Management LLC Black Diamond Therapeutics, Inc. Transaction History
Dafna Capital Management LLC
- $368 Million
- Q4 2024
A detailed history of Dafna Capital Management LLC transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Dafna Capital Management LLC holds 140,000 shares of BDTX stock, worth $232,400. This represents 0.08% of its overall portfolio holdings.
Number of Shares
140,000
Previous 125,000
12.0%
Holding current value
$232,400
Previous $543,000
44.94%
% of portfolio
0.08%
Previous 0.14%
Shares
5 transactions
Others Institutions Holding BDTX
# of Institutions
94Shares Held
47.6MCall Options Held
2.9KPut Options Held
69.4K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.5MShares$17.4 Million0.01% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$14.1 Million0.36% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$9.3 Million0.71% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$7.38 Million0.68% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$5.34 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $60.3M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...